Effect of phenothiazines on central cholinergic activity.
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001921:Brain / Q000201:enzymology; D001923:Brain Chemistry / Q000187:drug effects; D002746:Chlorpromazine / Q000627:therapeutic use; D002794:Choline / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002802:Cholinesterases / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010830:Physostigmine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012110:Reserpine / Q000494:pharmacology; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced; D014268:Trifluoperazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D014268:Trifluoperazine; D012110:Reserpine; D010830:Physostigmine; D002802:Cholinesterases; D002794:Choline; D000109:Acetylcholine; D002746:Chlorpromazine